Abstract
Type 1 diabetes mellitus is known to be associated with reduced bone mass and increased bone fractures. This is thought to be due to a decrease in osteoblastic bone formation rather than an increase in osteoclastic bone resorption, but the precise mechanism is unknown. In this study, we examined whether or not high glucose or advanced glycation end-products (AGEs), which play key roles in the pathogenesis and complications of diabetes, affect the differentiation of osteoblastic MC3T3-E1 cells. First, MC3T3-E1 cells were incubated in media containing either 22 mM glucose, 22 mM mannitol, 300 μg/ml AGE2, or 300 μg/ml AGE3. Each of these agents alone did not affect the mineralization of the cells by von Kossa staining and Alizarin red staining. However, high glucose but not mannitol or AGEs markedly increased mRNA expression of AGE receptor (RAGE) by real-time PCR. Next, we examined the combined effects of high glucose and AGEs on the differentiation of MC3T3-E1 cells. The combination of 22 mM glucose and 300 μg/ml AGE2 significantly inhibited the mineralization of MC3T3-E1 cells, and 22 mM glucose in combination with either 300 μg/ml AGE2 or AGE3 apparently decreased osteocalcin mRNA expression. These results suggest that high glucose or AGEs alone might have no effect on osteoblastic differentiation, but their combination could additionally or synergistically inhibit osteoblastic mineralization through glucose-induced increase in RAGE expression.
Key words
diabetes mellitus - osteoblast - bone formation - differentiation - RAGE
References
1
Forsen L, Meyer HE, Midthjell K, Edna TH.
Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey.
Diabetologia.
1999;
42
920-925
2
Nicodemus KK, Folsom AR.
Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.
Diabetes Care.
2001;
24
1192-1197
3
Raskin P, Stevenson MR, Barilla DE, Pak CY.
The hypercalciuria of diabetes mellitus: its amelioration with insulin.
Clin Endocrinol (Oxf).
1978;
9
329-335
4
Ishida H, Cunningham NS, Henry HL, Norman AW.
The number of 1,25-dihydroxyvitamin D3 receptors is decreased in both intestine and kidney of genetically diabetic db/db mice.
Endocrinology.
1988;
122
2436-2443
5
Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E.
Effects of high concentrations of glucose on PTH secretion in parathyroid cells.
Kidney Int.
1990;
37
1522-1527
6
Jehle PM, Jehle DR, Mohan S, Bohm BO.
Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients.
J Endocrinol.
1998;
159
297-306
7
Bouillon R, Bex M, Van Herck E, Laureys J, Dooms L, Lesaffre E, Ravussin E.
Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus.
J Clin Endocrinol Metab.
1995;
80
1194-1202
8
Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, MacCabe LR.
Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.
Endocrinology.
2005;
146
3622-3631
9
Brenner RE, Riemenschneider B, Blum W, Morike M, Teller WM, Pirsig W, Heinze E.
Defective stimulation of proliferation and collagen biosynthesis of human bone cells by serum from diabetic patients.
Acta Endocrinol (Copenh).
1992;
127
509-514
10
Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, Morii H, Otani S.
Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells.
Bone.
1998;
22
17-23
11
Botolin S, MacCabe LR.
Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways.
J Cell Biochem.
2006;
99
411-424
12
Gopalakrishnan V, Vignesh RC, Arunakaran J, Aruldhas MM, Srinivasan N.
Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages.
Biochem Cell Biol.
2006;
84
93-101
13
Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita Z.
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes.
Biochem Biophys Res Commun.
2002;
290
973-978
14
Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z.
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells.
J Biol Chem.
2002;
277
20309-20315
15
Sekido H, Suzuki T, Jomori T, Takeuchi M, Yabe-Nishimura C, Yagihashi S.
Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells.
Biochem Biophys Res Commun.
2004;
320
241-248
16
Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S.
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction.
Kidney Int.
2004;
66
2137-2147
17
Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, Sato B, Okada S, Kishimoto T.
Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells.
J Bone Miner Res.
1997;
12
439-446
18
Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S.
Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy.
Am J Kidney Dis.
2001;
38
S161-S164
19
Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N.
Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia.
J Bone Miner Res.
1996;
11
931-937
20
Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S.
In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria.
J Cell Biol.
1983;
96
191-198
21
Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K.
Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone.
J Bone Miner Res.
2005;
20
1647-1658
22
Alikhani M, Alikhani Z, Boyd C, Maclellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT.
Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways.
Bone.
2007;
40
345-353
23
Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, MacCarthy AD.
Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK).
Mol Cell Biochem.
2003;
250
1-10
24
Hatakeyama D, Kozawa O, Niwa M, Matsuno H, Ito H, Kato K, Tatematsu N, Shibata T, Uematsu T.
Upregulation by retinoic acid of transforming growth factor-beta-stimulated heat shock protein 27 induction in osteoblasts: involvement of mitogen-activated protein kinases.
Biochim Biophys Acta.
2002;
1589
15-30
25
Tokuda H, Hatakeyama D, Akamatsu S, Tanabe K, Yoshida M, Shibata T, Kozawa O.
Involvement of MAP kinases in TGF-beta-stimulated vascular endothelial growth factor synthesis in osteoblasts.
Arch Biochem Biophys.
2003;
415
117-125
26
Kanno Y, Ishisaki A, Yoshida M, Tokuda H, Numata O, Kozawa O.
SAPK/JNK plays a role in transforming growth factor-beta-induced VEGF synthesis in osteoblasts.
Horm Metab Res.
2005;
37
140-145
27
Noda T, Tokuda H, Yoshida M, Yasuda E, Hanai Y, Takai S, Kozawa O.
Possible involvement of phosphatidylinositol 3-kinase/Akt pathway in insulin-like growth factor-I-induced alkaline phosphatase activity in osteoblasts.
Horm Metab Res.
2005;
37
270-274
28
Takai S, Tokuda H, Hanai Y, Kozawa O.
Phosphatidylinositol 3-kinase/akt plays a part in tumor necrosis factor-alpha-induced interleukin-6 synthesis in osteoblasts.
Horm Metab Res.
2006;
38
563-569
Correspondence
T. Yamaguchi
Department of Internal Medicine 1
Shimane University Faculty of Medicine
89-1 Enya-cho
Izumo
693-8501 Shimane
Japan
Phone: +81/853/20 21 83
Fax: +81/853/23 86 50
Email: yamaguch@med.shimane-u.ac.jp